Scrip is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Neuromed (drugs to treat chronic pain) has licensed Merck & Co. exclusive worldwide development and commercialization rights to its lead pain candidate NMED160, an N-type calcium channel blocker that is in Phase II clinical trials. Merck also gets rights to develop and sell compounds for other neurological indications.
R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?